Americans are racist per se.[1]

Regarding your request for an investigation by the Department of Justice, FDA reiterates that such requests should be addressed to the appropriate State and Federal authorities. As for a ban on "Provastin," we do not find any drug product by that name to be marketed in the United States, so no action is warranted.

Citizen Petition Dated July 21, 1993
(FDA Docket No. 93P-0301/CP1)

This citizen petition requests that President Clinton and Secretary of Health and Human Services Donna E. Shalala review your petition, and that the Commissioner order an investigation of Squibb/Novo for allegedly defrauding shareholders and employees and violating corporation laws. Your petition also made allegations against various individuals, companies, universities, and others for supposedly engaging in, among other things, criminal activity and violating civil rights laws.

The agency denies your requests. We reiterate that FDA's authority is defined by the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. Your requests involve matters that are outside the agency's jurisdiction, and we suggest that you direct your requests to the appropriate State and Federal authorities.

Conclusion

For the reasons stated above, your petition for reconsideration and citizen petitions are denied.

Sincerely yours,

for Ronald G. Chesemore
Associate Commissioner
for Regulatory Affairs

Enclosure

---

[1] Indeed, with respect to hypertension, the available data indicate that hypertension is more prevalent in African Americans than in whites. See Cornoni-Huntley, J., LaCroix, A.Z., and Havlik, R.J., "Race and Sex Differentials in the Impact of Hypertension in the United States," Arch. Intern. Med. 149:780-788 (1989).

UNITED STATES PRESIDENT
COMMISSIONER DAVID KESSLER
FEDERAL BUREAU OF INVESTIGATION, JOHN BOWED 5/28/90
DEPARTMENT OF TREASURY, ALCOHOL, FIREARMS AND TOBACCO ACT
UNITED STATES DISTRICT COURT IP 95953HDG
POLICE COMMISSIONER HOWARD SAFIR, 17TH PCT & 105 PCT, VILLAGE OF HEMPSTEAD

June 24, 1996

STATEMENT OF FACT

THE INJUNCTIVE RELIEF GIVEN TO TRIAL JUDGE RAYMOND DEARIE AND MAGISTRATE AZRACK WAS GIVEN IN PERJURY AND DEFAULT SQUIBB UNDER NEW YORK STATE WORKERS' COMPENSATION LAW TO DENY THE INGESTION OF DRUGS AND ITS EFFECT ON MR. LOUIS P. WARDEN'S BODY

ATTENTION: Mr. Robert Enderies - Application for Wholesale Distributor's licence throughout the U.S. dated 7/15/93

Mr. Robert Redmond NYS Department of Labor. The Filing of false and fraudulent documents as to the illegal Squibb and successor Squibb upon Robert Enderies' application to defraud Medicaid with a dangerous drug licence (see letter June 13, 1996 Karen B. Cohan).

The documents filed with Delaware State Board of Pharmacy verified by Paul Davis, Karen Davis and Governor Thomas Capers were filed with the intent to defraud the state of Delaware upon transfer of licence of Squib (E.R. Squibb and Sons, A.K.A. Squibb/Novo) that changed the trademark, sale of stock and change of name Squibb to commit shareholder fraud, consumer fraud, denial of long-term disability by Frank Fossi documented by the U.S. Security Exchange Commission 5/17/94 and Wall Street, August 10, 1994 which reported Squibb/Novo dismantled.

Bristol Myers/Squibb has denied knowledge association with Squibb or Novo Nordisk in default as employer concealed before judge Raymond Dearie as successor to Squibb given to NYS Department of Insurance 6/12/90.

In conclusion, this matter is given as ordered by U.S. President to Post Master Henry Johnson to verify licence and registration upon postal services paid to document Squibb/Novo now Novo Nordisk to legally ship drugs, syringes, radioactive materials, nuclear drugs and narcotics (**Noctec as testified by Nicholas Cartesio to deny ingestion of drugs**). The licence and registration are not transferable from Olin Mathieson Chemical Corporation now E.R. Squibb and Sons. **David Ross, Esq and Lina Liberatore and Kathleen Meriwether committed perjury to judge Dearie's letter 7/13/95.**

cc: *Kenneth Kalano*, State of New Jersey
CN 369 Trenton NJ 086250369
Office of the Secretary HHS
Business and Administrative law, Room 5382
Cohan Building 330 Independence Ave, Washington DC.
Mr. Robert Redmond, NYS Department of Labor and NYSWCB, Chairman's Office

Louis P. Warden

Twenty in rush to adopt miracle baby
Page 2

Win $10,000 on Wall Street – New game starts today
See Page 21 for details

World's top heroin dealers hauled to N.Y.
Page 2

NEW YORK POST
LATE CITY FINAL
MONDAY, APRIL 17, 1995 / Bright sun today, 60s / Details, Page 28 / 50¢

SPECIAL POST INVESTIGATION

$150M MEDICAID SCAM



- Street hustlers are using bogus ailments to get drugs
- Greedy doctors and clinics are billing for work that's not necessary
- Black marketeers pocket a bundle renting cards and reselling drugs

Full report: Pages 4, 5 & 11

U. S. Securities Exchange
U. S. Dept of Justice Sally Thompson
Secretary HHS and African Conspiracy

Judges Bureau and U.S. Senate Chief Justice William Rhenquist of High Crimes and Misdemeanors upon decision of Squibb/Novo 97-75-90 and Injunctive Relief denied by Judges Parker, Leval and Gabranes - See KKK 1-9-99.

Issue: Kinko's was notified and informed of a crack cocaine, illegal syringes and sell of devices done through there chain. The Kinko's Management has faxed the "Squibb" E.R. Squibb and Sons aka Novo Nordisk, etc.

Kinko's Copiers and the White Crack and Cocaine Dealers called New White girl on the block causing Sexual Dysfunction Cause #140688 - See Congress Investigation John Dingel

To: Kinko's Copiers
Manager of Chain, California

Attention: Congressman Dan Burton
Congressman John Dingel / Senator Spencer
Indiana Methodist Hospital and SKF

Pursuant to Congressional Investigation and Kathy Browner in case 97-75-90 attach this illegal drug firm has no registration, incorporation, license to sell under formerly as (Squibb).

On 2/9/99 a well known Indianapolis Star writer was told of Eli Lilly bigotry in the article attached by the City Sun.

Ms. Marshall of Dateline of 20/20 is aware of the illegal BMS document called by Senior Judge Jack Weinstein New Issues Federal Judge Ray Dearie was engaged in criminal activity of tampering of an illegal agreement by an illegal lawyer that Gov. Christine Todd Whitman is protecting under to set the Black Vote.

Pursuant to these facts document under cause #140688 that Wausau Insurance under Judge David Hamilton, Judge John Tinder and the FDA have all engaged in an assault upon the Hoosier Public to conceal crimes.

Gov. Frank O'Bannon was served with letters. This filed with the conference clerk of the KKK of the Black KKK. Gov. George Pataki and Gary Penna has Squibb in default of Judge Farrell Jones award and David Ross theft of the Novo related activities.

David Ross has stated that Novo was not related to Squibb in forging stockholder vote on 4/20/89 to illegal enter the U.S.A. 2/25/82 case 95-953-HDG.

_____

Louis P. Warden

Chief Judge R. Poswer
Chief Judge W. Bureau
Chief Judge D. Manison

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NOV 9 1992

Louis P. Warden
P.O. Box 311
West Hempstead, New York 11552

Re: Docket No. 91P-0503/CP1

Dear Mr. Warden:

This letter responds to your December 12, 1991, citizen petition and May 21, 1992, supplement. You requested that the Food and Drug Administration take action with regard to the following matters:

1. A request that Commissioner Kessler "enforce his remarks in the New England Journal of Medicine" of July 18, 1991. Petition at 1.

2. An allegation that your former employer was involved in improper or illegal promotion and marketing practices. Petition at 2.

3. An allegation that "the interlocking relationship of such as (Squibb-Novo) a marketing agreement with an [sic] foreign company to capture market can result in diversion of samples, (novilin pens) sample accountability and the importation of tapes, video cassettes and books with drug being labeled 'free-trade items' with no sample." Petition at 2-3.

4. An allegation that the International Society of Hypertension in Blacks (ISHIB) is involved in a conflict of interest, unfair labor practices, and interference with your employment. Petition at 1.

5. An allegation that ISHIB fosters an incorrect image about hypertension in Blacks. Petition at 1-4.

6. Alleged violations of the New York Criminal Code. Petition at 3.

7. A request that the United States Department of Justice investigate alleged misconduct on the part of ISHIB in collaboration with the American Heart Association, National Heart Blood and Lung Institute, unspecified black groups, and FDA. Petition at 3.

8. Alleged misconduct with regard to your severance from employment. Petition at 3-4.

U.S. Pharmaceuticals
P.O. Box 4500 Princeton, NJ 08543-4500 609 897-2000

June 13, 1996

Mr. M. Faulks
FAX # 718-949-0115

Thank you for your inquiry regarding the manufacturing and distribution of insulin by Bristol-Mye Squibb.

Insulin previously manufactured by E.R. Squibb and Sons is now being manufactured and distribute by Novo Nordisk. Bristol-Myers Squibb is not affiliated with Novo Nordisk.

For additional information, please contact Novo Nordisk at the following address and phone numbe

100 Overlook Drive, Suite 200
Princeton, NJ 08540
1(800)-727-6500

Thank you for your interest in Bristol-Myers Squibb.

Sincerely,

Karen B. Cohen, Pharm.D.
Manager, Drug Information

faxed 6/13/9

ThePrudential

The Prudential Insurance Company of America
National Account Operations
56 North Livingston Avenue, P.O. Box 2900
Roseland, NJ 07068

April 19, 1995

Mr. Louis P. Warden
PO Box 311
West Hempstead, NY 11550

Dear Mr. Warden:

Your recent inquiry has been referred to me.

Prudential did not insured Squibb Nova. We were the administrator for the E.R. Squibb medical and dental plans and continue to administer the Bristol-Myers Squibb plans.

Sincerely,

Linda Barrett

Linda Barrett
Account Manager
National Account Operations

LB:sl/s:\docs\prnncap\lbarrett\ltr.12-13

cc: G. Furlong

REGISTRATION OF PRODUCERS OF DRUGS [52] AND DEVICES [53]

SEC. 510. [360] [53, 54, 55] (a) As used in this section—

(1) the term "manufacture, preparation, propagation, compounding, or processing" shall include repackaging or otherwise changing the container, wrapper, or labeling of any drug package or device package in furtherance of the distribution of the drug or device from the original place of manufacture to the person who makes final delivery or sale to the ultimate consumer or user; and

(2) the term "name" shall include in the case of a partnership the name of each partner and, in the case of a corporation, the name of each corporate officer and director, and the State of incorporation.

(b) On or before December 31 of each year every person who owns or operates any establishment in any State engaged in the manufacture, preparation, propagation, compounding, or processing of a drug or drugs or a device or devices shall register with the Secretary his name, places of business, and all such establishments.

(c) Every person upon first engaging in the manufacture, preparation, propagation, compounding, or processing of a drug or drugs or a device or devices in any establishment which he owns or operates in any State shall immediately register with the Secretary his name, place of business, and such establishment.

(d) Every person duly registered in accordance with the foregoing subsections of this section shall immediately register with the Secretary any additional establishment which he owns or operates in any State and in which he begins the manufacture, preparation, propagation, compounding, or processing of a drug or drugs or a device or devices.

(e) The Secretary may assign a registration number to any person or any establishment registered in accordance with this section. The Secretary may also assign a listing number to each drug or class of drugs listed under subsection (j). Any number assigned pursuant to the preceding sentence shall be the same as that assigned pursuant to the National Drug Code. The Secretary may by

---

[52] The Congress hereby finds and declares in order to make regulation of interstate commerce in drugs effective, it is necessary to provide for registration and inspection of all establishments in which drugs are manufactured, prepared, propagated, compounded, or processed; that the products of all such establishments are likely to enter the channels of interstate commerce and directly affect such commerce; and that the regulation of interstate commerce in drugs without provision for registration and inspection of establishments that may be engaged only in intrastate commerce in such drugs would discriminate against and depress interstate commerce in such drugs, and adversely burden, obstruct, and affect such interstate commerce. Amended by sec. 701 of P.L. 91-513.

[53] Secs. 10 and 11 of P.L. 89-74 apply to certain provisions in sec. 510 and to all of sec. 511. Secs. 10 and 11 of P.L. 89-74 provide that—

Nothing in this Act shall be construed as authorizing the manufacture, compounding, processing, possession, sale, delivery, or other disposal of any drug in any State in contravention of the laws of such State.

No provision of this Act nor any amendment made by it shall be construed as indicating an intent on the part of the Congress to occupy the field in which such provision or amendment operates to the exclusion of any State law on the same subject matter, unless there is a direct and positive conflict between such provision or amendment and such State law so that the two cannot be reconciled or consistently stand together.

No amendment made by this Act shall be construed to prevent the enforcement in the courts of any State of any statue of such State prescribing any criminal penalty for any act made criminal by such amendment.

[54] Subsec. (a)(2) repealed and sec. (a)(3) redesignated as sec. (a)(2) by sec. 701 of P.L. 91-513. Subsec. (b), (c), (d) amended by sec. 701 of P.L. 91-513.

[55] Sec. 510 amended by sec. 4 of P.L. 94-295.



Attn Warden
1133 Belmont St
Indianapolis Indiana
46222

Office of the Secretary
Public Health Servic
Food & Drug
5600 Fisaher Lane
Rockville MD 20857

16.70

FDA Docket 93P/0301/CP